Brain Oligometastasis in NSCLC (OligoLung)

University Hospital of Bordeaux

Status

Active, not recruiting

Conditions

Non-small Cell Lung Cancer

Brain Oligometastatic

Treatments

Other: Standard treatments / multiple strategies

Study type

Observational

Funder types

Other

Identifiers

NCT07389642

CHUBX 2025/058

Details and patient eligibility

About

75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized. The question is therefore which therapeutic strategy is optimal in such disease presentation. We will analyze the impact of different therapeutic strategies on patients treated at Bordeaux University Hospital and the Bergonié Institute

Full description

75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized. The question is therefore which therapeutic strategy is optimal in terms of disease control: local treatment of the main tumor and brain versus systemic treatment with chemotherapy and immunotherapy. We will analyze the impact of these 2 strategies on patients treated at Bordeaux University Hospital and the Bergonié Institute.

Enrollment

46 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

Consecutive patients managed at Bordeaux University Hospital
Non-small-cell lung cancer
Oligometastatic brain cancer (fewer than 5 lesions at diagnosis)
Patient over 18 years old

Exclusion criteria

Oncogenic addiction EGFR, ALK, ROS1
Patient with concomitant cancer
Patient with prior treatment for lung cancer in the year preceding diagnosis at metastatic stage